Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA

Full Text:

Abstract

.

Keywords


About the Author

Bayer Company Press Release

Russian Federation


References

1. Eikelboom, JW, Connolly SJ, Bosch J, et al. N Engl J Med 2017; 377:1319-1330.


For citation:


Press Release B. Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA. Rational Pharmacotherapy in Cardiology. 2018;14(5):797. (In Russ.)

Views: 54


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)